US3441741077 - Common Stock
FOGHORN THERAPEUTICS INC
NASDAQ:FHTX (5/17/2024, 7:00:00 PM)
After market: 5.51 0 (0%)5.51
-0.3 (-5.16%)
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 161 full-time employees. The company went IPO on 2020-10-23. Its Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within the system. The Company’s Traffic Control platform discovers and develops drugs in oncology and other therapeutic areas, including virology, autoimmune disease and neurology. The firm is developing FHD-286, a selective, allosteric ATPase inhibitor and which is evaluating two separate Phase I studies in metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia, and myelodysplastic syndrome. The company is also developing FHD-609, a targeted protein degrader, and which is evaluating in a Phase I study in synovial sarcoma.
FOGHORN THERAPEUTICS INC
500 Technology Square, Suite 700
Cambridge MASSACHUSETTS 02139
P: 16175863100
CEO: Adrian Gottschalk
Employees: 161
Website: https://foghorntx.com/
Third research collaboration signed under strategic partnership between Novo Nordisk and Flagship Pioneering to develop novel treatment approaches for...
FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Foghorn Therapeutics (NASDAQ:FHTX) just reported results for the first quarter ...
Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a...
Here you can normally see the latest stock twits on FHTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: